Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (56)

I-025Arwa Alghaith

Understanding the effect of administration schedule on the efficacy of olaparib-radiation combination therapy for glioblastoma using Bayesian PKPD modelling

Wed, Jun 3, 2026 10:30AM–12:00PM

I-026Marçal Bravo i Padrós

JOINT MODELING OF TUMOR SIZE AND PROGRESSION-FREE SURVIVAL (PFS) TO SUPPORT PHASE 3 DOSE SELECTION OF ODRONEXTAMAB PLUS CHEMOTHERAPY IN PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Wed, Jun 3, 2026 10:30AM–12:00PM

I-027

M-PROTEIN DYNAMIC METRICS TO SUPPORT EARLY DRUG DEVELOPMENT DECISIONS IN MULTIPLE MYELOMA

Wed, Jun 3, 2026 10:30AM–12:00PM

I-028Miro Julian Eigenmann

Impact of soluble BCMA on the PKPD assessment and dose selection for BCMA 4-1BBL

Wed, Jun 3, 2026 10:30AM–12:00PM

I-029Peng Man

IMMORTAL TIME BIAS IN USING IMMUNE-MEDIATED ADVERSE EVENTS AS PREDICTORS OF SURVIVAL: INSIGHTS FROM A MULTISTATE MODELING APPROACH

Wed, Jun 3, 2026 10:30AM–12:00PM

I-030Lisa Hanquet

CAR-T PERSISTENCE MODELLING: BRIDGING BIOLOGY AND DATA

Wed, Jun 3, 2026 10:30AM–12:00PM

I-031Anne Keunecke

Population PK/PD analysis of roginolisib in healthy participants using the basophil activation test to determine the PI3Kδ occupancy.

Wed, Jun 3, 2026 10:30AM–12:00PM

I-032Brett Matzuka

Semi-Mechanistic Population PKPD model of linvoseltamab in Multiple Myeloma

Wed, Jun 3, 2026 10:30AM–12:00PM

I-033Adam Nasim

TMDD modeling for antibodies directed against soluble targets: parameter values for de novo modeling and simulation from experimental data.

Wed, Jun 3, 2026 10:30AM–12:00PM

I-034Andrew Dwi Permana

AI-DRIVEN EARLY DETECTION OF COLORECTAL CANCER USING LONGITUDINAL AND MULTIMODAL ELECTRONIC HEALTH RECORDS IN SWEDISH PRIMARY HEALTH CARE

Wed, Jun 3, 2026 10:30AM–12:00PM

I-035Carmine Schiavone

A Scalable, Open-Source PBPK-QSP Framework for Translating the Safety and Efficacy of Bispecifics T-Cell Engager

Wed, Jun 3, 2026 10:30AM–12:00PM

I-036Rob Ter Heine

Translational modelling of pembrolizumab reveals a knowledge gap in immune checkpoint inhibitor dose development

Wed, Jun 3, 2026 10:30AM–12:00PM

I-037Isis Van herteryck

Impact of the use of different PK/PD indexes on amikacin dosing requirements in severely ill children: a population PK approach

Wed, Jun 3, 2026 10:30AM–12:00PM

I-038Chenyu Wang

Experimental and Virus-Specific Drivers of EC50 Variability in Antiviral Assays Evaluated Using Mathematical Modeling

Wed, Jun 3, 2026 10:30AM–12:00PM

II-025Ahmed Atta

Mechanistic Modeling of Radiation-Induced Immune Responses in Normal Lung Tissue

Wed, Jun 3, 2026 3:20PM–4:50PM

II-026Fabian Cardozo

PRECURSOR-POOL MODEL OF CYTOKINE KINETICS IN PATIENTS RECEIVING LINVOSELTAMAB

Wed, Jun 3, 2026 3:20PM–4:50PM

II-027Suthunya Chupradit

POPULATION PHARMACOKINETICS OF MYCOPHENOLIC ACID IN PATIENTS WITH HIGH-GRADE LOCALLY ADVANCED OR METASTATIC OSTEOSARCOMA

Wed, Jun 3, 2026 3:20PM–4:50PM

II-028Lola FÉRÉ GELY

Mechanistic–Latent Class Modeling to Improve Response Classification in «Mouse Clinical Trials»

Wed, Jun 3, 2026 3:20PM–4:50PM

II-029Masato Fukae

APPLICATION OF DEEPNLME FRAMEWORK TO CHARACTERIZE DISTINCT PLATELET DYNAMICS IN PATIENTS TREATED WITH MILADEMETAN

Wed, Jun 3, 2026 3:20PM–4:50PM

II-030Eva Helmer

INFLUENCE OF NON-ADHERENCE ON THE ESTIMATION OF PHARMACOKINETIC PARAMETERS OF CABOZANTINIB IN RENAL CELL CARCINOMA

Wed, Jun 3, 2026 3:20PM–4:50PM

II-031Frederic Lusoli

Using deconvolution to support the development of an abemaciclib parent-metabolite joint pharmacokinetic model

Wed, Jun 3, 2026 3:20PM–4:50PM

II-032Anna Mc Laughlin

A MECHANISM-BASED PARSIMONIOUS CAR-T CELL POPULATION PK MODEL AND ITS VALIDATION VIA EXTENSION TO A POPULATION PK-TUMOR SIZE DYNAMICS MODEL: CASE STUDY WITH AXICABTAGENE CILOLEUCEL AND BREXUCABTAGENE AUTOLEUCEL

Wed, Jun 3, 2026 3:20PM–4:50PM

II-033Anna-Kristina Oma

Population pharmacokinetics supports pembrolizumab de-escalation while meeting target exposure in advanced non-small cell lung cancer

Wed, Jun 3, 2026 3:20PM–4:50PM

II-034Ruediger E. Port

MIXED-EFFECTS MODELING OF THE PLASMA KINETICS OF THE ANTI-CD8 PET TRACER [18F]-2C8v144 AND THE NON-BINDING CONTROL TRACER [18F]-2C8V145 ENABLES ESTIMATES OF THE TOTAL AMOUNT OF CD8 IN THE BODY AND THE FRACTION PRESENT IN BLOOD, AND THE EQUILIBRIUM DISSOCIATION CONSTANT (K_D) OF [18F]-2C8v144; AND PREDICTIONS OF TOTAL BODY RECEPTOR OCCUPANCY BY [18F]-2C8v144

Wed, Jun 3, 2026 3:20PM–4:50PM

II-035Dmitry Shchelokov

Quantitative Systems Pharmacology Modeling to Explore Alternative Step-Up Dosing Regimens for Tarlatamab, a DLL3-Targeting T-Cell Engager

Wed, Jun 3, 2026 3:20PM–4:50PM

II-036Hoai-Thu Thai

Isatuximab SC versus IV in patients with Relapsed/Refractory Multiple Myeloma: Insights from longitudinal PK/PD Analysis of Serum M-Protein in the non-inferiority IRAKLIA Trial

Wed, Jun 3, 2026 3:20PM–4:50PM

II-037Areti-Maria Vasilogianni

Cancer-Driven Changes in Small Intestinal and Colonic Drug-Metabolising Enzymes and Transporters: Updating Cancer Populations for PBPK Modelling and Pharmacokinetic Implications

Wed, Jun 3, 2026 3:20PM–4:50PM

II-038Romain Zakrajsek

Mechanistic modeling of the natural history of cancer progression and metastatic dissemination in stage I non-small cell lung cancer patients after curative surgery

Wed, Jun 3, 2026 3:20PM–4:50PM

III-025Daniel Bending

Challenges in Extending Semi-Mechanistic Neutropenia Models to Antibody-Drug Conjugate and Chemotherapy Combinations: Implications for G-CSF Dosing Optimisation

Thu, Jun 4, 2026 9:50AM–11:20AM

III-026Daniel Centanni

An Integrated Population Pharmacokinetic Analysis of Peg-Asparaginase Across Multiple Nordic Acute Lymphoblastic Leukemia Treatment Protocols: Characterizing Time-Dependent Clearance Dynamics and Patient Factors Driving Variability

Thu, Jun 4, 2026 9:50AM–11:20AM

III-027

PK/PD modelling and simulations of cambritaxestat-mediated inhibition of autotaxin-lysophosphatidic acid pathway in metastatic pancreatic cancer patients to inform Phase II dose selection

Thu, Jun 4, 2026 9:50AM–11:20AM

III-028Richard Franzese

Joint modeling of tumor size and circulating tumor DNA dynamics to predict overall survival in non-small cell lung cancer

Thu, Jun 4, 2026 9:50AM–11:20AM

III-029Gaston Garcia-Orueta

A semi-mechanistic model describing tumor response to oncolytic virus and anti-PD-1 therapy in preclinical studies

Thu, Jun 4, 2026 9:50AM–11:20AM

III-030Vincent Hurez

USE OF VIRTUAL TWINS TO ESTABLISH A PREDICTIVE MODEL BETWEEN SIMULATED IL-6 CONCENTRATIONS AND CRS RISK DURING ODRONEXTAMAB STEP-UP DOSING IN B-CELL LYMPHOMA PATIENTS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-031Mathilde Marchand

A PREDICTIVE MODELING FRAMEWORK TO RECONSTRUCT AND SIMULATE PFS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-032Anna Mishina

Application of a Simulation-Based Diagnostics for Survival Evaluation in Joint Models

Thu, Jun 4, 2026 9:50AM–11:20AM

III-033Zinnia P Parra-Guillen

A population modelling framework to support early clinical development of BI-1206, a monoclonal antibody blocking FcγRIIB

Thu, Jun 4, 2026 9:50AM–11:20AM

III-034Neelima Patnaikuni

AN IN-SILICO APPROACH TO SUPPORT THE ANTIBODY DRUG CONJUGATE (ADC) COMBINATIONS TRIAL DESIGN: IMPACT OF PROPHYLACTIC RESCUE ON EFFICACY

Thu, Jun 4, 2026 9:50AM–11:20AM

III-035Elsa Hélène Smith

Limited pharmacokinetic and pharmacodynamic modelling research of
lymphodepleting agents in CAR-T cell therapy: a literature review

Thu, Jun 4, 2026 9:50AM–11:20AM

III-036Huybrecht T'jollyn

MODEL-INFORMED DRUG DEVELOPMENT TO SUPPORT DOSE SELECTION OF PASRITAMIG, A KLK2×CD3 BISPECIFIC ANTIBODY, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Thu, Jun 4, 2026 9:50AM–11:20AM

III-037Alina Volkova

A Model-Informed Quantitative Framework for First-in-Human Dose Selection of T-Cell Receptor Mimetics in Acute Myeloid Leukemia

Thu, Jun 4, 2026 9:50AM–11:20AM

III-038Sybrand Zielhuis

The relationship between pre-operative ipilimumab and nivolumab pharmacokinetics and treatment outcome in locoregionally advanced urothelial cancer

Thu, Jun 4, 2026 9:50AM–11:20AM

IV-024Ludovica Aiello

Development of a mathematical model for the quantitative comparison of RC106 and TMZ efficacy in U87 spheroids

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-025Alieke Bos

A REPEATED TIME-TO-EVENT ANALYSIS OF LENVATINIB-INDUCED DOSE-LIMITING TOXICITIES IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND METASTATIC RENAL CELL CARCINOMA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-026Marc Cerou

Model-based assessment of isatuximab monthly dosing regimen in relapsed/refractory multiple myeloma patients using IKEMA phase 3 data

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-027Birses Debir

MECHANISTIC MODELLING OF CRS IN T CELL ENGAGERS – AN APPLICATION FOR BLINATUMOMAB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-028Tomoko Freshwater

MODEL-INFORMED DOSAGE SELECTION FOR GOCATAMIG, A TRI-SPECIFIC, HALF-LIFE–EXTENDED DLL3-DIRECTED T-CELL ENGAGER IN PATIENTS WITH SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-029Juan Antonio Garzón Lamarque

INTEGRATED POPULATION SEMI-MECHANISTIC PK/PD MODELING OF HIGH-DOSE METHOTREXATE AND 6-MERCAPTOPURINE EFFECTS ON NEUTROPHIL DYNAMICS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-030Jiyeon Jeon

Exposure–response evaluation and simulation studies of IMC-001 using a model incorporating FcRn recycling

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-031John Maringwa

Model Based Meta-Analysis of Disease-Free Survival in Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Treated with Mitomycin C or Gemcitabine

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-032Aparna Mohan

QUANTITATIVE SYSTEMS PHARMACOLOGY GUIDED MABEL ESTIMATION FOR T-CELL ENGAGERS (TCE): A CASE STUDY TO SUPPORT MODEL-INFORMED FIRST-IN-HUMAN DOSE SELECTION

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-033Carlos Perez-Ruixo

POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS OF TECLISTAMAB IN COMBINATION WITH DARATUMUMAB IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR LINE OF THERAPY.

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-034Daniela Santurio

APPLICATION OF IO SIMULATOR IN IMMUNO-ONCOLOGY COMBINATION THERAPY: A SMALL CELL LUNG CANCER CASE STUDY

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-035Chrisoula Tahtsidou

FROM CAPILLARY TO CLINIC: MODEL-BASED TRANSLATION OF VOLUMETRIC ABSORPTIVE MICROSAMPLING CONCENTRATIONS FOR THERAPEUTIC DRUG MONITORING OF CABOZANTINIB

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-036Debra Van Asten

Population pharmacokinetics of [177Lu]Lu-PSMA-617 combined with EBRT and ADT in treatment naïve patients: differences in tumor uptake and cycle-dependent-effects

Thu, Jun 4, 2026 1:40PM–3:10PM

IV-037Chen Wang

PREDICTING PROGRESSION-FREE SURVIVAL FOR ABSK-011 (IRPAGRATINIB) IN ADVANCED FGF19+ HCC PATIENTS VIA JOINT MODELING OF TUMOR GROWTH DYNAMICS

Wed, Jun 3, 2026 10:30AM–12:00PM